Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 66Terminated 15Recruiting 4Active not recruiting 4Not yet recruiting 3Withdrawn 2Unknown 2No longer available 1

Sponsor Class

OTHER 31NIH 4NETWORK 3INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Myeloid 1

Interventions

Injections 54Cisplatin 48Paclitaxel 47Carboplatin 43Gemcitabine 38pembrolizumab 36Docetaxel 35Capecitabine 35Drug Therapy 34anlotinib 25Bevacizumab 25Cyclophosphamide 24icotinib 23Fluorouracil 23fludarabine 19Oxaliplatin 19Pemetrexed 17Leucovorin 16Irinotecan 15Temozolomide 14Nivolumab 14Doxorubicin 14Cetuximab 14camrelizumab 13apatinib 13Trastuzumab 12Rituximab 11Fulvestrant 11Etoposide 11tesetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Imatinib Mesylate × Clear all
NCT02317159 2014-12-15

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Cttq

Phase 4 Unknown
90 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01503502 2013-04-10

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
150 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡